Ziopharm Oncology (NASDAQ:ZIOP) has announced that its investigational new drug (IND) application which was submitted by the National Cancer Institute (NIC) received clearance from the US Food and Drug Administration (FDA) for a clinical trial in solid tumors to test T-cell receptor (TCR) T-cell therapy using the company’s Sleeping Beauty platform. As quoted in the … Continued
The post Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial appeared first on Investing News Network.